Dyne Therapeutics, Inc. (DYN) Stock Price & Analysis

Dyne Therapeutics, Inc. (DYN) closed at USD 16.98 on Wednesday, October 28, 2026, up 0.24% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 16.94; the Oct 28, 2026 session ranged USD 16.17–17.12 on volume of 2,176,074 shares. Market capitalization is $3.17B, with a 52-week range of USD 14–27.31 (NMS). Source: Nexqual, retrieved October 28, 2026 at 21:24 UTC.

Also available as compact Markdown for AI agents: nexqual.com/DYN.md

Key facts (DYN)

• Insider open-market sales, last ~7 months: 29 Form 4 filings, $153M; 1 not under a Rule 10b5-1 plan ($48K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 5 Form 4 filings, $197K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (17 analysts), mean target USD 36 (range 10–50).
• Total return with dividends: 1Y -28.1% vs S&P 500 +13.6%; 5Y +17.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD -0.89, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DYN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (DYN)

P/B 4.5x · FCF yield -15.15% · Earnings yield -16.38% · Net cash $699M · EV $2.47B

Insider sales (SEC Form 4, open-market, last ~7 months) (DYN)

28 of 29 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (DYN)

5 purchases, $197K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (DYN)

Consensus Buy (mean 2.00 on a 1–5 scale), 17 analysts; mean target USD 36 (low 10, high 50).

Rating changes, last 120 days:

Total return (dividends reinvested) (DYN)

DYN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

DYN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

DYN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 2, 2026.

Companies that name DYN in their SEC reports

DYN company outlook (results filed Jul 29, 2026)

• “PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 - - Investigational New Drug (IND) Application cleared by FDA for DYNE-302 in FSHD - - Expected cash runway into Q2 2028 - WALTHAM, Mass., July 29, 2026 – Dyne Therapeutics, Inc.”
• “The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with the net proceeds from the July 2026 underwritten public offering, will be sufficient to fund its operations into the second quarter of 2028.”
• “The words 3 "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will" or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.”

Quoted word-for-word from the SEC 8-K results press release.

DYN analyst estimates and revisions

DYN options: expected move

Options price a move of about ±14.0% (±$2.33) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±7.7% on average.

30-day implied volatility 67.2% vs 57.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 21:24 UTC)

Technical Analysis (DYN)

Nexqual's technical model rates DYN "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 28, 2026 at 21:24 UTC.

Analyst Ratings (DYN)

Wall Street analysts rate DYN "Buy" based on 17 analysts, with a mean price target of USD 36 (range USD 10–50), per Nexqual as of October 28, 2026 at 21:24 UTC.

Earnings (DYN)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Financials & Fundamentals (DYN)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Financial Health Score (DYN)

Nexqual rates Dyne Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 21:24 UTC.

Ownership (DYN)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

Leadership (DYN)

Dyne Therapeutics, Inc. is led by John G. Cox, CEO, President & Director, per Nexqual as of October 28, 2026 at 21:24 UTC.

Major Backers & Investors (DYN)

Notable institutional backers of Dyne Therapeutics, Inc. include T. Rowe Price, Jupiter Topco LLC, FMR, LLC, according to Nexqual as of October 28, 2026 at 21:24 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 21:24 UTC.

From Dyne Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• We strive to protect our proprietary technology, inventions, improvements, platforms, program candidates, product candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining, defending and enforcing patent and other intellectual property rights for the foregoing in the United States and in foreign jurisdictions.
• Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS.
• We have designed our proprietary FORCE platform using our deep knowledge of muscle biology.
• We engineered our proprietary Fab to bind to TfR1 to enable targeted delivery to skeletal, cardiac and smooth muscle, and TfR1 binding may also enable delivery to the CNS.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not be able to obtain orphan drug exclusivity for product candidates we may develop, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products.
• We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business.
• Our relationships with healthcare providers, physicians and third-party payers will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
• Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 21:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt